Inhibition/NN
of/IN
human/JJ
immunodeficiency/NN
virus/NN
type/NN
1/CD
replication/NN
in/FW
vitro/FW
by/IN
a/DT
novel/JJ
combination/NN
of/IN
anti-Tat/JJ
single-chain/JJ
intrabodies/NNS
and/CC
NF-kappa/NN
B/NN
antagonists/NNS
./.

Human/JJ
immunodeficiency/NN
virus/NN
type/NN
1/CD
(/(
HIV-1/NN
)/)
Tat/NN
,/,
an/DT
early/JJ
regulatory/JJ
protein/NN
that/WDT
is/VBZ
critical/JJ
for/IN
viral/JJ
gene/NN
expression/NN
and/CC
replication/NN
,/,
transactivates/VBZ
the/DT
HIV-1/NN
long/JJ
terminal/JJ
repeat/NN
(/(
LTR/NN
)/)
via/IN
its/PRP$
binding/NN
to/TO
the/DT
transactivation/NN
response/NN
element/NN
(/(
TAR/NN
)/)
and/CC
,/,
along/IN
with/IN
other/JJ
cellular/JJ
factors/NNS
,/,
increases/VBZ
viral/JJ
transcription/NN
initiation/NN
and/CC
elongation/NN
./.
=====
Tat/NN
also/RB
superactivates/VBZ
the/DT
HIV-1/NN
promoter/NN
through/IN
a/DT
TAR-independent/JJ
mechanism/NN
,/,
including/VBG
tumor/NN
necrosis/NN
factor/NN
alpha-induced/JJ
and/CC
protein/NN
kinase/NN
C/NN
(/(
PKC/NN
)/)
-dependent/JJ
activation/NN
of/IN
NF-kappa/NN
B/NN
,/,
and/CC
inhibitors/NNS
of/IN
Tat/NN
and/CC
NF-kappa/NN
B/NN
cooperatively/RB
down-regulate/VBP
this/DT
Tat-mediated/JJ
LTR/NN
superactivation/NN
./.
=====
In/IN
this/DT
study/NN
,/,
a/DT
combined/JJ
pharmacologic/JJ
and/CC
genetic/JJ
strategy/NN
using/VBG
two/CD
PKC/NN
(/(
NF-kappa/NN
B/NN
)/)
inhibitors/NNS
,/,
pentoxifylline/NN
(/(
PTX/NN
)/)
and/CC
Go-6976/NN
,/,
and/CC
a/DT
stably/RB
expressed/VBN
anti-Tat/JJ
single-chain/JJ
intracellular/JJ
antibody/NN
(/(
sFv/NN
intrabody/NN
)/)
was/VBD
employed/VBN
to/TO
obtain/VB
cooperative/JJ
inhibition/NN
of/IN
both/CC
HIV-1/NN
LTR-driven/JJ
gene/NN
expression/NN
and/CC
HIV-1/NN
replication/NN
./.
=====
Treatment/NN
of/IN
cells/NNS
with/IN
PTX/NN
and/CC
Go-6976/NN
resulted/VBD
in/IN
cooperative/JJ
inhibition/NN
of/IN
both/CC
HIV-1/NN
LTR-driven/JJ
gene/NN
expression/NN
and/CC
HIV-1/NN
replication/NN
./.
=====
In/IN
addition/NN
,/,
the/DT
combined/JJ
use/NN
of/IN
anti-Tat/JJ
sFv/NN
intrabodies/NNS
and/CC
the/DT
two/CD
NF-kappa/NN
B/NN
inhibitors/NNS
retained/VBD
the/DT
virus/NN
in/IN
the/DT
latent/JJ
state/NN
for/IN
as/RB
long/JJ
as/IN
45/CD
days/NNS
./.
=====
The/DT
combined/JJ
treatment/NN
resulted/VBD
in/IN
more/RBR
durable/JJ
inhibition/NN
of/IN
HIV-1/NN
replication/NN
than/IN
was/VBD
seen/VBN
with/IN
the/DT
NF-kappa/NN
B/NN
inhibitors/NNS
alone/RB
or/CC
the/DT
anti-Tat/NN
sFv/NN
intrabodies/NNS
alone/RB
./.
=====
Together/RB
,/,
these/DT
results/NNS
suggest/VBP
that/IN
in/IN
future/JJ
clinical/JJ
gene/NN
therapy/NN
trials/NNS
,/,
a/DT
combined/JJ
pharmacologic/JJ
and/CC
genetic/JJ
strategy/NN
like/IN
the/DT
one/CD
reported/VBN
here/RB
may/MD
improve/VB
the/DT
survival/NN
of/IN
transduced/VBN
cells/NNS
and/CC
prolong/VB
clinical/JJ
benefit/NN
./.